Sherbrooke Park Advisers LLC Lowers Holdings in Phreesia, Inc. (NYSE:PHR)

Sherbrooke Park Advisers LLC lessened its stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 67.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,042 shares of the company's stock after selling 28,525 shares during the quarter. Sherbrooke Park Advisers LLC's holdings in Phreesia were worth $353,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Johnson Financial Group Inc. raised its stake in shares of Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock worth $28,000 after purchasing an additional 896 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Phreesia during the fourth quarter worth approximately $30,000. BankPlus Trust Department purchased a new stake in shares of Phreesia during the fourth quarter worth approximately $34,000. Quarry LP raised its stake in shares of Phreesia by 210.9% during the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock worth $71,000 after purchasing an additional 1,923 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Phreesia during the fourth quarter worth approximately $76,000. Hedge funds and other institutional investors own 92.10% of the company's stock.

Phreesia Price Performance

Phreesia stock traded down $0.27 during trading hours on Friday, hitting $24.07. The stock had a trading volume of 242,602 shares, compared to its average volume of 439,105. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -16.37 and a beta of 0.74. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $30.53. The stock's fifty day moving average is $25.18 and its two-hundred day moving average is $25.19.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a research report on Thursday, March 13th. KeyCorp cut their price objective on Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. DA Davidson cut their price objective on Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Piper Sandler reiterated an "overweight" rating and issued a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Finally, Wall Street Zen cut Phreesia from a "buy" rating to a "hold" rating in a research report on Saturday. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat, Phreesia currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.33.

Insider Buying and Selling at Phreesia

In related news, General Counsel Allison C. Hoffman sold 1,213 shares of the stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $23.81, for a total transaction of $28,881.53. Following the sale, the general counsel now owns 137,921 shares of the company's stock, valued at $3,283,899.01. This trade represents a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Balaji Gandhi sold 1,827 shares of the stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $27.46, for a total value of $50,169.42. Following the sale, the chief financial officer now directly owns 103,591 shares in the company, valued at approximately $2,844,608.86. The trade was a 1.73% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,474 shares of company stock valued at $1,023,208. Insiders own 5.80% of the company's stock.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.